IN Brief:
- Four new corridors connect Frankfurt, Atlanta, Chicago, Narita, Brussels, and São Paulo.
- Kuehne+Nagel now operates 12 qualified lanes for temperature sensitive healthcare freight.
- Controlled airport handling can support lighter passive packaging while limiting exposure outside specified temperatures.
Kuehne+Nagel has added four airfreight routes to its Cool Corridor network for temperature sensitive healthcare products, increasing the system to 12 qualified lanes across Europe, North America, Asia, and Latin America.
The new connections link Frankfurt with Atlanta, Chicago with Narita, Brussels with São Paulo, and Chicago with São Paulo. They are intended for vaccines, biologics, peptides, and other pharmaceuticals whose quality can be affected by extended exposure outside specified temperature ranges.
The Frankfurt to Atlanta route includes dedicated weekly capacity aboard Kuehne+Nagel’s Boeing 747 freighter, Inspire. The remaining lanes use contracted airline capacity combined with controlled handling and transfer procedures at origin and destination.
Each Cool Corridor operates through agreed processes covering shipment acceptance, build up, airport storage, aircraft transfer, breakdown, and collection. Kuehne+Nagel, airlines, and ground handlers follow a common Good Distribution Practice framework rather than treating each handover as a separate operating environment.
Traditional pharmaceutical airfreight frequently uses active containers with powered cooling systems, particularly when a route involves several transfers or uncertain dwell periods. Active equipment provides strong protection but adds weight, rental cost, positioning requirements, charging, and return logistics.
A controlled corridor can reduce part of that exposure by managing the environment around the package. Where the lane qualification supports it, a lighter passive system may provide sufficient protection without moving a large powered container with every shipment.
The packaging decision remains specific to the product, season, route, and expected journey. Passive systems must account for ambient temperature, airport waiting time, customs clearance, flight changes, and the possibility that a shipment will remain in transit longer than planned.
“With more confidence in shipment conditions, customers can use lighter passive packaging, creating opportunities to reduce logistics costs and transport emissions without compromising product integrity,” said Dorothee Becher, vice president of global air logistics healthcare at Kuehne+Nagel.
Reducing packaging and shipment weight can lower airfreight expenditure and emissions, although the advantage disappears quickly if a delayed movement requires emergency repacking, replacement refrigerants, or a complete reshipment. Consistent handling remains central to both the commercial and environmental calculation.
Pharmaceutical supply chains are becoming more geographically dispersed as active ingredients, formulation, filling, packaging, testing, and distribution take place at specialised sites. A single medicine may cross several borders before reaching the market, increasing the number of airport and handling interfaces attached to each batch.
Manufacturers consequently place considerable value on repeatable routes with qualified contingency plans. A cancelled flight should lead to a prearranged alternative using suitable storage and handling, rather than an improvised diversion through a location without the same controls.
DSV has developed a comparable connection through its Luxembourg to Indianapolis pharmaceutical corridor, linking two healthcare clusters through a dedicated handling and air capacity model.
Investment is also increasing around production and final distribution. Eisai’s Hatfield cold chain expansion is adding storage and handling capacity as biologics and other sensitive medicines occupy a larger share of pharmaceutical output.
The new São Paulo routes extend the network into a market where customs processing and long inland distribution legs can add variability after the flight has arrived. Narita connects the service with a mature Japanese pharmaceutical sector whose quality and documentation requirements leave little tolerance for inconsistent handovers.
Condition monitoring can reveal where time outside the target environment accumulates, allowing handlers to revise transfer sequences, staffing, or storage arrangements. Those records also support investigation when a shipment arrives with a temperature excursion or delayed delivery history.
The four additions broaden the number of production and market pairs that can remain inside a managed operating framework. Their value will be determined by performance during irregular operations, when capacity shortages, weather, customs delays, and missed connections place the greatest pressure on product integrity.
A qualified lane does not remove those disruptions, but it replaces a chain of loosely connected handovers with a defined set of responsibilities and contingency procedures. For high value medicines, that consistency can carry more weight than a marginal reduction in scheduled transit time.
